GAM Holding AG Grows Position in DexCom, Inc. (NASDAQ:DXCM)

GAM Holding AG grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 17.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,177 shares of the medical device company’s stock after purchasing an additional 1,647 shares during the period. GAM Holding AG’s holdings in DexCom were worth $763,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in DXCM. Private Trust Co. NA lifted its stake in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the period. Optiver Holding B.V. acquired a new stake in shares of DexCom during the 4th quarter valued at approximately $33,000. TD Private Client Wealth LLC boosted its stake in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after acquiring an additional 137 shares during the period. Finally, Heck Capital Advisors LLC purchased a new position in DexCom in the 4th quarter valued at approximately $38,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

DexCom stock opened at $80.00 on Friday. The stock has a fifty day moving average price of $80.08 and a 200 day moving average price of $79.39. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $117.19. The firm has a market capitalization of $31.37 billion, a P/E ratio of 59.70, a PEG ratio of 1.71 and a beta of 1.46. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the company earned $0.32 EPS. The company’s revenue was up 12.5% compared to the same quarter last year. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In related news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $41,400.00. Following the transaction, the executive vice president now owns 95,102 shares in the company, valued at approximately $7,874,445.60. This trade represents a 0.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the transaction, the director now owns 56,621 shares in the company, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 25,724 shares of company stock valued at $2,157,034 in the last ninety days. Company insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on DXCM shares. The Goldman Sachs Group initiated coverage on DexCom in a research report on Friday, May 30th. They set a “buy” rating and a $104.00 target price on the stock. Wall Street Zen upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Saturday. Piper Sandler lowered their price objective on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating on the stock in a research note on Friday, May 2nd. Truist Financial initiated coverage on shares of DexCom in a research report on Monday, June 16th. They set a “buy” rating and a $102.00 target price for the company. Finally, Mizuho initiated coverage on shares of DexCom in a report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.